3-[1,2,3,6-TETRAHYDROPYRIDIN-2-YL]PYRIDINE GLUTARATE OR PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF Russian patent published in 2024 - IPC C07D401/04 A61K31/444 A61P25/28 A61P29/00 A61P5/16 

Abstract RU 2823979 C2

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine glutarate. Method of producing glutarate 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine, with ratio of 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine to glutarate 1:1, includes steps of obtaining solution containing 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine, glutaric acid and a solvent; heating obtained solution; providing formation of salt of 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine with glutaric acid and extraction of salt of 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine of glutaric acid, where said solvent used to obtain solution of 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine, glutaric acid and the solvent is acetonitrile. Obtained 3-[1,2,3,6-tetrahydropyridin-2-yl]pyridine glutarate is in a polymorphic form which has an X-ray powder diffraction pattern (CuKα), containing three or more peaks selected from 8.0 ± 0.2°2θ, 11.0 ± 0.2°2θ, 13.3 ± 0.2°2θ, 16.5 ± 0.2°2θ, 18.0 ± 0.2°2θ, 20.7 ± 0.2°2θ, 21.0 ± 0.2°2θ, 21.4 ± 0.2°2θ, 22.0 ± 0.2°2θ, 22.3 ± 0.2°2θ, 23.3 ± 0.2°2θ and 24.5 ± 0.2°2θ.

EFFECT: obtaining anatabine glutarate, having such properties as high degree of crystallinity, storage stability, low level of hygroscopicity, fluidity.

5 cl, 1 tbl, 14 dwg, 6 ex

Similar patents RU2823979C2

Title Year Author Number
CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE, SUITABLE FOR TREATMENT OF ABNORMAL GROWTH OF CELLS IN MAMMALS 2008
  • Kehmpeta Ehntoni Majkl
  • Chekal Brajan Patrik
  • Maklaflin Robert Uill'Jam
  • Singer Robert Alan
RU2518898C2
METHODS OF PRODUCTION ISOQUINOLINONES AND SOLID FORMS ISOQUINOLINONES 2012
  • Zhen Pinda
  • Martin Majkl
  • Izbester Pol
  • Lejn Bendzhamin S.
  • Kropp Dzhejson
RU2626883C2
POLYMORPHOUS AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL)BUTANAMIDE 2015
  • Mollard Pol
  • Kornel Kristofer R.
  • Vesson Kiron E.
  • Dzhannusis Piter
  • Sachit Shazad
  • Mirmekhrabi Makhmud
RU2770091C2
SOLID FORMS OF SELECTIVE CDK4/6 INHIBITOR 2014
  • Chekal Brian Patrick
  • Ide Nathan D.
RU2619944C2
POLYMORPHIC FORMS OF ICOTINIB AND USES THEREOF 2014
  • Hu, Shaojing
  • Long, Wei
  • Wang, Fei
  • Wang, Yinxiang
  • Ding, Lieming
RU2710013C2
POLYMORPHIC MODIFICATION IN N-{5-[3-(THIOPHENE-2-CARBONYL)-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL]-2-FLUORO-PHENYL}-N-METHYL-ACETAMIDE (VERSIONS), CONTAINING IT PHARMACEUTICAL COMPOSITION (VERSIONS), MEDICATION, METHOD OF OBTAINING SAID POLYMORPHIC MODIFICATION (VERSIONS) AND METHOD OF TREATMENT AND/OR PREVENTION OF NERVOUS DISORDERS 2007
  • Anglada Luis
  • Gul'Etta Antonio
  • Palomer Al'Bert
RU2413729C2
POLYMORPHS OF ARRY-380, SELECTIVE INHIBITOR OF ERB2, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 2012
  • Korson Donald T.
  • Lindemann Kristofer M.
  • Vatson Deniel Dzh.
RU2629116C2
SOLID FORMS OF THE COMPOUND MODULATING THE KINASES 2016
  • Ibrakhim Prabkha N.
  • Vajzor Geri Konrad
RU2730506C2
POLYMORPHIC FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMIN FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS 2007
  • Dall Gari Moris
  • Mun'Os Khulio A.
RU2440984C2
CRYSTALLINE FORM OF MALEATE OF CONDENSED PYRIDINE DERIVATIVE AND METHODS FOR USE THEREOF 2016
  • Hu, Shaojing
  • Long, Wei
  • Zhou, Liufeng
  • Xu, Zhiguo
  • Wang, Fei
RU2712280C2

RU 2 823 979 C2

Authors

Mazurov, Anatoly

Dates

2024-07-31Published

2019-12-17Filed